Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

NNASDAQ:CNTB
0.64
USD
-0.03
(-5.05%)
-1.19EPS
149.88MMarket Cap
Nov 18Next Earn
Connect Biopharma Holdings Limited
NASDAQ:CNTB
(Nasdaq Stock Market)

Recent

price

0.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
0.47
- -
0.05
Revenue per Share
-0.06
-0.34
-3.87
-2.15
-1.13
-0.28
-1
-1.19
Basic EPS, GAAP
-0.03
-0.08
-1.75
-1.92
-0.87
-0.44
-0.93
-1.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.11
-0.45
4.94
2.86
1.84
1.67
0.74
0.43
Book Value per Share
-0.11
-0.45
4.88
2.8
1.84
1.66
0.74
0.43
Tangible Book Value per Share
55
54
52
55
55
55
56
58
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
26
- -
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-86.24
-90,740.62
-2,384.49
Operating Margin (%)
- -
- -
1
1
1
1
1
1
Depreciation Expense
-3
-18
-202
-118
-62
-16
-55
-69
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-60.03
-86,687.5
-2,336.3
Profit Margin (%)
7
24
257
140
97
88
37
22
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-6
-24
272
157
101
92
42
27
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-54.96
-47.96
-16.14
-82.72
-140.51
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
56
63
63
Market Capitalization
159
164
150

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
51
55
39
Cash, Cash Equivalents & STI
44
46
31
Accounts Receivable, Net
- -
- -
3
Inventories
- -
- -
- -
Total Current Liabilities
14
17
16
Payables & Accruals
10
15
14
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-274.74%
-54.45%
Free Cash Flow
- -
412.97%
111.97%
Net Income, GAAP
- -
219.54%
255%
Sales/Revenue/Turnover
- -
- -
-99.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
24
1
1
26
2025
- -
- -
- -
- -
- -
2026
- -
3
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.16
0.27
-0.23
-0.16
-0.28
2025
-0.19
-0.23
-0.31
-0.27
-1
2026
-0.34
-0.27
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Connect Biopharma Holdings Limited (CNTB) is a clinical-stage global biopharmaceutical company focused on developing T cell-driven therapies for chronic inflammatory diseases, including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, ulcerative colitis, Crohn's disease, and pruritus; its pipeline features rademikibart (formerly CBP-201), a next-generation monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα) to block IL-4 and IL-13 signaling, advancing in Phase 2 trials for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) with topline data expected in the first half of 2026, Phase 3 asthma maintenance studies ongoing via partner Simcere in China where a New Drug Application for atopic dermatitis was submitted to the National Medical Products Administration in July 2025, and prior Phase 2/3 data in atopic dermatitis, asthma, and chronic rhinosinusitis; icanbelimod (formerly CBP-307), an oral small molecule sphingosine 1-phosphate receptor 1 (S1P1) modulator in Phase 2 for ulcerative colitis and Crohn's disease; and CBP-174, a peripherally acting histamine receptor 3 antagonist in early clinical development for pruritus in atopic dermatitis. Founded in 2012 and headquartered in San Diego, California, the company operates primarily in the United States with additional facilities in Taicang, Jiangsu Province, China, and South San Francisco, California, targeting patients with T cell-mediated inflammatory conditions through small molecules and antibodies discovered via proprietary functional T cell assays. Recent developments include leadership strengthening in 2024 with Barry Quart, Pharm.D., appointed as CEO and David Szekeres as President to enhance clinical, regulatory, and operational expertise; a strategic shift to a U.S.-centric focus with reduced China footprint and unveiled rapid development program for rademikibart in acute respiratory care; regained Nasdaq minimum bid price compliance; plans to terminate its American Depositary Receipt program and directly list ordinary shares on Nasdaq; presentations of supporting rademikibart data at the European Respiratory Society Congress 2025; and ongoing collaboration with Simcere for rademikibart commercialization in Greater China, generating minimal revenue of $64,000 year-to-date in 2025 amid elevated R&D costs for the asset.

Company News

  • Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript

  • Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

  • Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

  • Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast

  • Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

  • Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

  • Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

  • Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

  • Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

  • Why Is Connect Biopharma Stock Trading Lower on Tuesday?

  • Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

  • Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29

  • Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

  • Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

  • Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

  • Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

  • Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

  • Connect Biopharma: New Market Opportunity In The Emergency Setting